Results 11 to 20 of about 10,116 (213)

Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]

Cochrane Database of Systematic Reviews, 2016
This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS, Castelão, M, Rodrigues, FB, Marques, RE, Ferreira, J, Sampaio, C, Moore, AP, Costa, J   +7 more
  +9 more sources

Botulinum toxin type A therapy for blepharospasm [PDF]

Cochrane Database of Systematic Reviews, 2020
This is an update of a Cochrane Review first published in 2005. Blepharospasm is the second most common form of focal dystonia. It is a disabling disorder, characterised by chronic, intermittent or persistent, involuntary eyelid closure, due to spasmodic contractions of the orbicularis oculi muscles.
Duarte, GS, Rodrigues, FB, Marques, RE, Castelão, M, Ferreira, J, Sampaio, C, Moore, AP, Costa, J   +7 more
openaire   +5 more sources

Botulinum Toxin Type a in Cervical Dystonia

International Journal of Immunopathology and Pharmacology, 2012
Cervical dystonia is a syndrome characterized by anomalous postures and unintentional repetitive movements of the head and the neck. Aim of this study is to show the effectiveness of the combined treatment botulinum toxin-FKT through the use of a recent methodic of investigation, myoton, and of the classical clinical evaluations, such as Tsui and VAS ...
Marvulli R., Ianieri G., Megna G., Lancioni G., SAGGINI, Raoul, Ranieri M., Cristella G., Megna M.   +7 more
openaire   +3 more sources

Evaluation of the botulinum toxin effects in the correction of gummy smile 32 weeks after application

ABCS Health Sciences, 2022
Introduction: The use of botulinum toxin type A (BTX-A) to correct gummy smile has become popular in recent years. Objective: To evaluate the effects of BTX-A application in the correction of gummy smile 2 and 32 weeks after application.
Carlos Eduardo Alonso Vieira, Wilson Rodrigues de Almeida, Paula Cotrin, Renata Cristina Gobbi de Oliveira, Ricardo Cesar Gobbi de Oliveira, Fabrício Pinelli Valarelli, Julie Watanabe Zamuner, Karina Maria Salvatore de Freitas   +7 more
doaj   +1 more source

Botulinum toxin in the treatment of pemphigus vegetans of the scalp [PDF]

Surgical & Cosmetic Dermatology
Pemphigus vegetans is a rare clinical form of pemphigus vulgaris, and scalp involvement is even rarer. Treatment can be challenging, often requiring systemic immunosuppression.
André Pozzobon Capeletti, Ana Paula Dornelles Manzoni, Rodrigo Pereira Duquia, Vanessa Vinderfeltes Padilha   +3 more
doaj   +1 more source

Preoperative botulinum toxin type A: A case report of a proposed new strategy for giant hiatal hernia management

Clinical Case Reports, 2020
The use of preoperative ventral botulinum toxin for giant hiatal hernia management.
Francisco Tustumi, Edno Tales Bianchi, Sérgio Szachnowicz, Rider May Cedro, Antonio Afonso deMiranda Neto, André Luiz Gioia Morrell, Ricardo Zugaib Abdalla, Rubens Antonio Aissar Sallum, Ivan Cecconello   +8 more
doaj   +1 more source

Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art

Toxins, 2021
Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide
Alessandro Picelli, Mirko Filippetti, Giorgio Sandrini, Cristina Tassorelli, Roberto De Icco, Nicola Smania, Stefano Tamburin   +6 more
doaj   +1 more source

The Use of Botulinum Toxin in the Treatment of Headache: an Integrative Literature Review

Headache Medicine, 2023
Full abstract in PDF.
Stephanie Bezerra Muniz Falcão, Pedro Serra Galdino Farias de Brito, Ellenicy Barbosa Oliveira, Ana Beatriz Rocha Rodrigues, Mariana Luna de Sales, Maria Eduarda Santos Diniz, Ítalo de Lima Farias, Ismael Lima Silva, Layla Beatriz Barroso de Alencar, Arthur Marques de Andrade, Joyce Raianne Santos Sá, Wictoria Gabrielle Lima de Oliveira, Renata de Souza Coelho Soares, Ana Isabella Arruda Meira Ribeiro, Gilma Serra Galdino   +14 more
doaj   +2 more sources

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis

Frontiers in Microbiology, 2022
Botulinum neurotoxin (BoNT) is one of the most dangerous bacterial toxins and a potential biological weapon component. BoNT mechanism of pathological action is based on inhibiting the release of neurotransmitters from nerve endings.
Artem A. Derkaev, Ekaterina I. Ryabova, Ilias B. Esmagambetov, Dmitry V. Shcheblyakov, Svetlana A. Godakova, Irina D. Vinogradova, Anatoly N. Noskov, Denis Y. Logunov, Boris S. Naroditsky, Alexander L. Gintsburg   +9 more
doaj   +1 more source

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome [PDF]

International Neurourology Journal, 2015
Intravesical onabotulinumtoxinA (BoNT-A) injection is an effective treatment for overactive bladder syndrome (OAB) that is refractory to antimuscarinics.
Chun-Hou Liao, Hann-Chorng Kuo
doaj   +1 more source